Stonepine Capital Management, LLC Quant / Systematic

Location: Bend, OR

CIK: 0001440771 · Show all filings

Period: Q4 2016 (← Previous) (Next →)

Filing Date: Feb 10, 2017

Total Value: $168M (89.7% shares, 10.3% debt)

Holdings (23)

Recro Pharma, Inc. 13.8%
Value $23.17M Shares 2,874,317 Est. Cost $8.20 Unrealized
Aegerion Pharmaceuticals, Inc. 10.3%
Value $17.24M Shares 24,200,000 Est. Cost $0.60 Unrealized
Alere Inc. 8.4%
Value $14.03M Shares 360,000 Est. Cost $42.05 Unrealized
Sciclone Pharmaceuticals, Inc. 8.0%
Value $13.49M Shares 1,249,200 Est. Cost $10.80 Unrealized
Viveve Medical, Inc 7.9%
Value $13.3M Shares 2,599,711 Est. Cost $7.22 Unrealized
Novelion Therapeutics, Inc. 7.6%
Value $12.83M Shares 1,524,034 Est. Cost $8.42 Unrealized
Ophthotech Corp 6.6%
Value $11.07M Shares 2,292,900 Est. Cost $4.83 Unrealized
Cardiome Pharma Corp 5.2%
Value $8.718M Shares 3,158,816 Est. Cost $2.98 Unrealized
ENTA Enanta Pharmaceuticals 4.6%
Value $7.769M Shares 231,913 Est. Cost $28.66 Unrealized 0.0%
VCYT Veracyte, Inc. 4.5%
Value $7.512M Shares 970,500 Est. Cost $7.48 Unrealized 0.0%
VCEL Vericel Corp 3.4%
Value $5.651M Shares 1,883,800 Est. Cost $2.52 Unrealized +1.9%
Alimera Sciences, Inc 3.0%
Value $4.985M Shares 4,615,813 Est. Cost $1.25 Unrealized
Biodelivery Sciences INTL 2.7%
Value $4.551M Shares 2,600,711 Est. Cost $1.75 Unrealized
Sucampo Pharmaceuticals - CL A 2.3%
Value $3.848M Shares 284,002 Est. Cost $13.55 Unrealized
CPIX Cumberland Pharmaceuticals, Inc. 2.0%
Value $3.407M Shares 619,538 Est. Cost $4.92 Unrealized +6.0%
Flamel Technologies - SP ADR 2.0%
Value $3.388M Shares 326,087 Est. Cost $10.39 Unrealized
Trinity Biotech PLC - SPON ADR 1.8%
Value $3.018M Shares 436,066 Est. Cost $6.92 Unrealized
Durect Corporation 1.7%
Value $2.918M Shares 2,177,791 Est. Cost $1.37 Unrealized
Mallinckrodt PLC 1.3%
Value $2.174M Shares 43,629 Est. Cost $49.83 Unrealized
Cutera, Inc. 1.2%
Value $2.089M Shares 120,429 Est. Cost $11.59 Unrealized
Juniper Pharmaceuticals, Inc. 0.8%
Value $1.279M Shares 228,392 Est. Cost $5.56 Unrealized
CTI Biopharma Corp 0.6%
Value $1.067M Shares 2,617,136 Est. Cost $0.41 Unrealized
Aviragen Therapeutics, Inc. 0.2%
Value $380K Shares 309,278 Est. Cost $1.48 Unrealized